Cocaine HCl was provided by the National Institute on Drug Abuse (Research Triangle Park, NC), and prepared in sterile 0.9% saline solution for intravenous administration. CRF (rat/human; Sigma Aldrich), CP376395 (Tocris Bioscience) and Astressin-2B (Tocris Bioscience) were prepared in aCSF, and stored in 20µL aliquots at −20°C until use. CRF doses were selected based on previous in vivo studies in rats (Kalivas et al. 1987 (link); Blacktop et al., 2011 (link); Wanat et al. 2013 (link)). A lower dose of CRF (50ng) was initially used in order to characterize the dose-response relationship, however, because the 500ng dose of CRF was ineffective in modulating cocaine-taking behavior during the binge-access procedure, only the 50ng dose was further examined (i.e. Experiments 2 and 3). Doses of antagonists were determined based on previous studies conducted in our laboratory (Boyson et al. 2014 (link); Holly et al. 2015 (link); 2016a (link))